Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study
Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study
DJ Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study
By Chris Wack
Sutro Biopharma Inc. said Thursday it has dosed the first patient in the dose-expansion cohort of its Phase 1 STRO-002 study.
STRO-002 is a folate receptor alpha targeting antibody-drug conjugate for the potential treatment of ovarian cancer.
The company said the dose-expansion cohort will assess the efficacy, safety and tolerability of STRO-002 at 4.3 and 5.2 mg/kg, given every three weeks in patients with ovarian cancer. The dose-expansion cohort for folate receptor alpha-selected endometrial cancer is planned for later this year.
Sutro said it plans to expand the study to 35 clinical sites in the U.S. and Europe. The dose-expansion study includes two patient cohorts, advanced epithelial ovarian cancer and endometrial cancer.
Sutro Biopharma shares were up 17% to $30.86 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 21, 2021 08:16 ET (13:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study
DJ Sutro Biophma剂量首例卵巢癌治疗研究
By Chris Wack
克里斯·瓦克(Chris Wack)著
Sutro Biopharma Inc. said Thursday it has dosed the first patient in the dose-expansion cohort of its Phase 1 STRO-002 study.
Sutro Biophma Inc.周四表示，它已经给其1期Stro-002研究的剂量扩展队列中的第一名患者开了药。
STRO-002 is a folate receptor alpha targeting antibody-drug conjugate for the potential treatment of ovarian cancer.
STRO-002是一种叶酸受体α靶向抗体-药物结合物，可用于卵巢癌的潜在治疗。
The company said the dose-expansion cohort will assess the efficacy, safety and tolerability of STRO-002 at 4.3 and 5.2 mg/kg, given every three weeks in patients with ovarian cancer. The dose-expansion cohort for folate receptor alpha-selected endometrial cancer is planned for later this year.
该公司表示，剂量扩大队列将评估Stro-002的有效性、安全性和耐受性，分别为4.3和5.2 mg/kg，用于卵巢癌患者，每三周服用一次。叶酸受体α选择的子宫内膜癌的剂量扩展队列计划在今年晚些时候进行。
Sutro said it plans to expand the study to 35 clinical sites in the U.S. and Europe. The dose-expansion study includes two patient cohorts, advanced epithelial ovarian cancer and endometrial cancer.
Sutro表示，计划将这项研究扩大到美国和欧洲的35个临床地点。剂量扩张研究包括两个患者队列，晚期上皮性卵巢癌和子宫内膜癌。
Sutro Biopharma shares were up 17% to $30.86 in premarket trading.
Sutro Biophma股价在盘前交易中上涨17%，至30.86美元。
Write to Chris Wack at chris.wack@wsj.com
写信给克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道琼通讯社
January 21, 2021 08:16 ET (13:16 GMT)
2021年1月21日东部时间08：16(格林尼治标准时间13：16)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧